Table 3 Pre and post descriptive statistics of frequency by question and domain (data are n (%))
Domain | Questions | Strongly disagree | Disagree | Neither agree nor disagree | Agree | Strongly agree | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
pre | post | pre | post | pre | post | pre | post | pre | post | ||
Perceptions around stopping medicines | Q1 | 0 (0%) | 0 (0%) | 4 (12.5%) | 0 (0%) | 8 (25.0%) | 3 (9.4%) | 16 (50%) | 23 (71.9%) | 4 (12.5%) | 6 (18.8%) |
Q2 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (6.3%) | 1 (3.1%) | 7 (21.9%) | 2 (6.3%) | 23 (71.9%) | 29 (90.6%) | |
Q3 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (9.4%) | 0 (0%) | 19 (59.4%) | 19 (59.4%) | 10 (31.3%) | 13 (40.6%) | |
Q4 | 0 (0%) | 0 (0%) | 1 (3.1%) | 0 (0%) | 2 (6.3%) | 1 (3.1%) | 20 (62.5%) | 18 (56.3%) | 9 (28.1%) | 13 (40.6%) | |
Knowledge and information sources | Q5 | 0 (0%) | 0 (0%) | 4 (12.5%) | 1 (3.2%) | 8 (25.0%) | 5 (16.1%) | 18 (56.3%) | 17 (54.8%) | 2 (6.3%) | 8 (25.8%) |
Q6 | 0 (0%) | 0 (0%) | 4 (12.5%) | 0 (0%) | 17 (53.1%) | 5 (16.1%) | 11 (34.4%) | 20 (64.5%) | 0 (0%) | 6 (19.4%) | |
Q7 | 0 (0%) | 0 (0%) | 5 (15.6%) | 0 (0%) | 3 (9.4%) | 2 (6.3%) | 19 (59.4%) | 22 (68.8%) | 5 (15.6%) | 8 (25.0%) | |
Q8 | 0 (0%) | 0 (0%) | 4 (12.5%) | 0 (0%) | 2 (6.3%) | 2 (6.5%) | 18 (56.3%) | 16 (51.6%) | 8 (25.0%) | 13 (41.9%) | |
Q9 | 1 (3.4%) | 0 (0%) | 0 (0%) | 1 (3.1%) | 0 (0%) | 3 (9.4%) | 4 (13.8%) | 14 (43.8%) | 24 (82.8%) | 14 (43.8%) | |
Q10 | 0 (0%) | 0 (0%) | 6 (18.8%) | 0 (0%) | 10 (31.3%) | 7 (21.9%) | 16 (50%) | 21 (65.6%) | 0 (0%) | 4 (12.5%) | |
Q11 | 0 (0%) | 0 (0%) | 5 (15.6%) | 4 (12.5%) | 4 (12.5%) | 7 (21.9%) | 21 (65.6%) | 17 (53.1%) | 2 (6.3%) | 4 (12.5%) | |
Perceptions of patients and stopping medicines | Q12 | 0 (0%) | 0 (0%) | 3 (9.4%) | 0 (0%) | 13 (40.6%) | 6 (18.8%) | 14 (43.8%) | 21 (65.6%) | 2 (6.3%) | 5 (15.6%) |
Q13 | 0 (0%) | 0 (0%) | 3 (9.4%) | 0 (0%) | 10 (31.3%) | 5 (15.6%) | 17 (53.1%) | 18 (56.3%) | 2 (6.3%) | 9 (28.1%) | |
Q14 | 0 (0%) | 0 (0%) | 3 (9.7%) | 0 (0%) | 8 (25.8%) | 5 (15.6%) | 19 (61.3%) | 21 (65.6%) | 1 (3.2%) | 6 (18.8%) | |
Perception of colleagues and stopping medicines | Q15 | 0 (0%) | 0 (0%) | 1 (3.1%) | 0 (0%) | 5 (15.6%) | 2 (6.3%) | 25 (78.1%) | 24 (75.0%) | 1 (3.1%) | 6 (18.8%) |
Q16 | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3.1%) | 6 (18.8%) | 4 (12.5%) | 25 (78.1%) | 19 (59.4%) | 1 (3.1%) | 8 (25.0%) | |
Q17 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 8 (25.0%) | 2 (6.3%) | 20 (62.5%) | 22 (68.8%) | 4 (12.5%) | 8 (25.0%) | |
Q18 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (6.7%) | 2 (6.3%) | 26 (86.7%) | 16 (50%) | 2 (6.7%) | 14 (43.8%) | |
Q19 | 0 (0%) | 0 (0%) | 2 (6.3%) | 0 (0%) | 14 (43.8%) | 10 (31.3%) | 16 (50%) | 19 (59.4%) | 0 (0%) | 3 (9.4%) | |
Q20 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (12.5%) | 5 (16.1%) | 27 (84.4%) | 16 (51.6%) | 1 (3.1%) | 10 (32.3%) | |
Q21 | 0 (0%) | 0 (0%) | 1 (3.1%) | 1 (3.1%) | 12 (37.5%) | 8 (25.0%) | 19 (59.4%) | 18 (56.3%) | 0 (0%) | 5 (15.6%) | |
Q22 | 6 (18.8%) | 6 (18.8%) | 12 (37.5%) | 10 (31.3%) | 10 (31.3%) | 5 (15.6%) | 4 (12.5%) | 7 (21.9%) | 0 (0%) | 4 (12.5%) | |
Q23 | 0 (0%) | 1 (3.1%) | 4 (12.5%) | 1 (3.1%) | 13 (40.6%) | 8 (25.0%) | 10 (31.3%) | 16 (50%) | 5 (15.6%) | 6 (18.8%) | |
Institutional factors | Q24 | 0 (0%) | 0 (0%) | 5 (15.6%) | 0 (0%) | 9 (28.1%) | 12 (37.5%) | 16 (50%) | 12 (37.5%) | 2 (6.3%) | 8 (25.0%) |
Q25 | 9 (28.1%) | 10 (31.3%) | 11 (34.4%) | 11 (34.4%) | 7 (21.9%) | 1 (3.1%) | 4 (12.5%) | 6 (18.8%) | 1 (3.1%) | 4 (12.5%) | |
Q26 | 10 (31.3%) | 14 (43.8%) | 11 (34.4%) | 13 (40.6%) | 8 (25.0%) | 3 (9.4%) | 1 (3.1%) | 2 (6.3%) | 2 (6.3%) | 0 (0%) | |
Q27 | 1 (3.1%) | 7 (21.9%) | 7 (21.9%) | 6 (18.8%) | 14 (43.8%) | 4 (12.5%) | 10 (31.3%) | 13 (40.6%) | 0 (0%) | 2 (6.3%) | |
Q28 | 0 (0%) | 0 (0%) | 2 (6.3%) | 2 (6.3%) | 13 (40.6%) | 4 (12.5%) | 17 (53.1%) | 18 (56.3%) | 0 (0%) | 8 (25.0%) | |